Pacer Advisors Inc. Boosts Position in Royalty Pharma plc (NASDAQ:RPRX)

Pacer Advisors Inc. lifted its position in Royalty Pharma plc (NASDAQ:RPRX) by 59.3% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 36,353 shares of the biopharmaceutical company’s stock after buying an additional 13,538 shares during the quarter. Pacer Advisors Inc.’s holdings in Royalty Pharma were worth $959,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of RPRX. Inspire Investing LLC boosted its holdings in Royalty Pharma by 175.1% in the 1st quarter. Inspire Investing LLC now owns 43,524 shares of the biopharmaceutical company’s stock valued at $1,322,000 after purchasing an additional 27,701 shares during the period. APG Asset Management US Inc. bought a new stake in Royalty Pharma during the fourth quarter valued at $2,100,000. New Century Financial Group LLC bought a new position in Royalty Pharma in the 1st quarter worth about $1,091,000. Patient Capital Management LLC bought a new position in Royalty Pharma in the 4th quarter worth about $35,247,000. Finally, Rhenman & Partners Asset Management AB boosted its position in shares of Royalty Pharma by 186.5% during the 4th quarter. Rhenman & Partners Asset Management AB now owns 429,697 shares of the biopharmaceutical company’s stock valued at $12,070,000 after acquiring an additional 279,697 shares during the last quarter. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Trading Up 0.1 %

RPRX stock opened at $28.21 on Friday. The company has a market capitalization of $16.74 billion, a PE ratio of 21.05, a price-to-earnings-growth ratio of 4.09 and a beta of 0.46. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35. Royalty Pharma plc has a one year low of $25.20 and a one year high of $31.66. The company’s 50 day moving average price is $28.01 and its two-hundred day moving average price is $27.93.

Royalty Pharma (NASDAQ:RPRX) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.01. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. The company had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $600.83 million. During the same quarter last year, the company earned $0.85 EPS. As a group, analysts predict that Royalty Pharma plc will post 4.04 earnings per share for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 13th. Stockholders of record on Friday, August 16th were paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date was Friday, August 16th. Royalty Pharma’s dividend payout ratio (DPR) is presently 62.69%.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. The Goldman Sachs Group upped their price objective on shares of Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Morgan Stanley lifted their price objective on shares of Royalty Pharma from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Finally, UBS Group cut Royalty Pharma from a “buy” rating to a “neutral” rating and set a $28.00 target price on the stock. in a research note on Monday, June 3rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $42.00.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.